The latest news and announcements from Rinascera Therapeutics.
Initial financing led by Double Point Ventures with participation from Olive Tree Capital, Civilization Ventures and Toba Capital supports advancement of RIN-001 for Gorlin Syndrome and RIN-002 for Dystrophic Epidermolysis Bullosa (DEB).